Engineered immune cells take on relapsed blood cancers in early trial
NCT ID NCT06765876
First seen Jan 12, 2026 · Last updated May 15, 2026 · Updated 24 times
Summary
This early-phase study tests a personalized cell therapy called CART123 for adults with certain blood cancers (like acute myeloid leukemia) that have not responded to standard treatments. Each patient's own immune cells are modified in a lab to target and attack cancer cells. The main goals are to check safety and find the best dose for future studies. Participants must be eligible for a stem cell transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES (MDS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ustav hematologie a krevni transfuze / Institute of Hematology and Blood Transfusion
RECRUITINGPrague, 12800, Czechia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.